

Two Year Longitudinal Evaluation of HRCT (Novartis PJMR005 2101)

Specimen Information

Status: Specimens are Available

Specimens for banking were collected at baseline and at various time points over a 2 year time frame. Longitudinal HRCT scans were evaluated in this study as well.

Visit #	Time From Baseline	Specimens Collected
3	+0 Days	EDTA plasma, Urine
4	+3 Months	EDTA plasma, Urine
5	+1 Years	EDTA plasma, Urine
6	+2 Years	EDTA plasma, Urine

Study Design

Study Type?	Observational
Randomized Study?	No
Placebo Controlled?	No
Length of Participation	2 Years
Number of Study Visits?	4

Additional Information

Phase?	Not Applicable
Study Sponsor?	Novartis
Study Drugs?	N/A

Eligibility

Age	7 Years to 18 Years
Mutation(s)	No Mutation Requirement
FEV1% Predicated	80 % or greater
PA Status	Not Applicable
Other	Subjects were required to be clinically stable at baseline.

Study Results

STUDY RESULTS NOT YET AVAILABLE